Nasdaq

Agilent Companion Diagnostic Expands CE-IVD Mark in Europe to Include Cervical Cancer

SANTA CLARA, Calif.--(BUSINESS WIRE)-- Agilent Technologies Inc. (NYSE: A) today announced that its PD-L1 IHC 22C3 pharmDx, Code SK006, is now EU CE-IVD–marked for use in cervical cancer. PD-L1 IHC ...
Business Wire

Fujirebio Europe Receives Distribution Rights to Market Self-screen's PreCursor-M+ Methylation-specific Molecular Assay, a Powerful Solution to Identify Women at High Risk for ...

GENT, Belgium & AMSTERDAM--(BUSINESS WIRE)--Fujirebio Europe and Self-screen B.V. today announce a commercial collaboration around the distribution of the PreCursor-M+ methylation-specific molecular ...
PharmiWeb

Cervical Cancer Screening Market ascent to US$ 5.7 billion by 2033 is influenced by rising prevalence and technological advancements | FMI

As per Future Market Insights’ latest industry analysis, the valuation for the global Cervical Cancer Screening Market is likely to reach US$ 1.6 Billion in 2023 and is projected to exhibit a CAGR ...
PR Newswire

Biotech Startup Noul Gets CE-IVD Mark for Two of miLab™ Cartridge Solutions

YONGIN, South Korea, Sept. 1, 2022 /PRNewswire/ -- Noul Co., Ltd., (376930.KR), a KOSDAQ-listed biotech startup, has obtained CE-IVD marks for two of its products. Based on this mark, Noul plans to ...
DutchNews.NL

Fujirebio Europe Receives Distribution Rights to Market Self-screen’s PreCursor-M+ Methylation-specific Molecular Assay, a Powerful Solution to Identify Women at High Risk ...

GENT, Belgium & AMSTERDAM–(BUSINESS WIRE)–#IVD–Fujirebio Europe and Self-screen B.V. today announce a commercial collaboration around the distribution of the PreCursor-M+ methylation-specific ...